Logo
x

Search category

Subscribe Now

UCB

UCB Reports the Commercial Availability of Rystiggo (rozanolixizumab-noli) for Adult Patients with Generalized Myasthenia Gravis in the US

UCB Reports the Commercial Availability of Rystiggo (rozanolixizumab-noli) for Adult Patients with Generalized Myasthenia Gravis i...

  • July 21, 2023
UCB’s Rystiggo (rozanolixizumab) Receives the US FDA’s Approval for the Treatment of Adults with Generalized Myasthenia Gravis

UCB’s Rystiggo (rozanolixizumab) Receives the US FDA’s Approval for the Treatment of Adults with Generalized Myasthenia Gravis

  • June 27, 2023
UCB’s Bimzelx (bimekizumab) Receives EC’s Marketing Authorisation for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

UCB’s Bimzelx (bimekizumab) Receives EC’s Marketing Authorisation for the Treatment of Psoriatic Arthritis and Axial Spondyloarthr...

  • June 7, 2023
UCB Entered into a Research Collaboration with Ariceum Therapeutics to Discover New Modalities for Immune-related Diseases and Cancer

UCB Entered into a Research Collaboration with Ariceum Therapeutics to Discover New Modalities for Immune-related Diseases and Can...

  • May 11, 2023
UCB Published P-III Studies (MycarinG) & (RAISE) of Rozanolixizumab and Zilucoplan for Generalized Myasthenia Gravis in The Lancet Neurology Journal

UCB Published P-III Studies (MycarinG) & (RAISE) of Rozanolixizumab and Zilucoplan for Generalized Myasthenia Gravis in The Lancet...

  • April 13, 2023
UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa

UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa

  • March 20, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.